In Vitro Exposure to PC-1005 and Cervicovaginal Lavage Fluid from Women Vaginally Administered PC-1005 Inhibits HIV-1 and HSV-2 Infection in Human Cervical Mucosa

التفاصيل البيبلوغرافية
العنوان: In Vitro Exposure to PC-1005 and Cervicovaginal Lavage Fluid from Women Vaginally Administered PC-1005 Inhibits HIV-1 and HSV-2 Infection in Human Cervical Mucosa
المؤلفون: Guillermo Villegas, Michael L. Cooney, Craig J. Hoesley, Olga Mizenina, Natalia Teleshova, Thomas M. Zydowsky, José A. Fernández-Romero, Kyle R. Kleinbeck, Barbara Friedland, George W. Creasy, Shimin Zhang, Giulia Calenda
بيانات النشر: American Society for Microbiology, 2016.
سنة النشر: 2016
مصطلحات موضوعية: 0301 basic medicine, Pyridines, Herpesvirus 2, Human, Zinc Acetate, HIV Infections, HSL and HSV, Antiviral Agents, Virus, Andrology, 03 medical and health sciences, chemistry.chemical_compound, Anti-Infective Agents, Microbicide, Medicine, Humans, Urea, Pharmacology (medical), Pharmacology, Herpes Genitalis, Mucous Membrane, business.industry, Coinfection, medicine.disease, In vitro, HIV Reverse Transcriptase, Carrageenan, Body Fluids, Microbicides for sexually transmitted diseases, Administration, Intravaginal, 030104 developmental biology, Infectious Diseases, chemistry, Vagina, HIV-1, Female, business, Gels, Explant culture
الوصف: Our recent phase 1 trial demonstrated that PC-1005 gel containing 50 μM MIV-150, 14 mM zinc acetate dihydrate, and carrageenan (CG) applied daily vaginally for 14 days is safe and well tolerated. Importantly, cervicovaginal lavage fluid samples (CVLs) collected 4 or 24 h after the last gel application inhibited HIV-1 and human papillomavirus (HPV) in cell-based assays in a dose-dependent manner (MIV-150 for HIV-1 and CG for HPV). Herein we aimed to determine the anti-HIV and anti-herpes simplex virus 2 (anti-HSV-2) activity of PC-1005 in human cervical explants after in vitro exposure to the gel and to CVLs from participants in the phase 1 trial. Single HIV-1 BaL infection and HIV-1 BaL –HSV-2 coinfection explant models were utilized. Coinfection with HSV-2 enhanced tissue HIV-1 BaL infection. In vitro exposure to PC-1005 protected cervical mucosa against HIV-1 BaL (up to a 1:300 dilution) in single-challenge and cochallenge models. CG gel (PC-525) provided some barrier effect against HIV-1 BaL at the 1:100 dilution in a single-challenge model but not in the cochallenge model. Both PC-1005 and PC-525 at the 1:100 dilution inhibited HSV-2 infection, pointing to a CG-mediated protection. MIV-150 and CG in CVLs inhibited HIV (single-challenge or cochallenge models) and HSV-2 infections in explants in a dose-dependent manner ( P < 0.05). Stronger inhibition of HIV-1 infection by CVLs collected 4 h after the last gel administration was observed compared to infection detected in the presence of baseline CVLs. The anti-HIV and anti-HSV-2 activity of PC-1005 gel in vitro and CVLs in human ectocervical explants supports the further development of PC-1005 gel as a broad-spectrum on-demand microbicide.
اللغة: English
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27e1d950925645eeffa690bda134e7b8
https://europepmc.org/articles/PMC4997862/
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....27e1d950925645eeffa690bda134e7b8
قاعدة البيانات: OpenAIRE